Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joan Maurel

Showing results (11-20 of 116) with videos related to

Pageof 12
Sort By:
International Journal of Cancer|October 22, 2014
Why post-progression survival and post-relapse survival are not appropriate measures of efficacy in cancer randomized clinical trialsXabier García-Albéniz, Joan Maurel, Miguel A Hernán
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 9, 2011
SEOM clinical guidelines for the treatment of anal cancerJoan Maurel, Carlos Fernández-Martos, Jaime Feliu, et al.
Cancers|August 17, 2019
The Tumor Microenvironment in Colorectal Cancer TherapyLeire Pedrosa, Francis Esposito, Timothy M Thomson, et al.
Journal of Clinical Medicine|March 6, 2021
Are Quality of Randomized Clinical Trials and ESMO-Magnitude of Clinical Benefit Scale Two Sides of the Same Coin, to Grade Recommendations for Drug Approval?Adela Rodriguez, Francis Esposito, Helena Oliveres, et al.
JCO Precision Oncology|May 18, 2026
EXONERATE-TRaCE: A Liquid Biopsy for Tracking Response to Anti-Epidermal Growth Factor Receptor-Based Therapy in Metastatic Colorectal CancerToshiaki Takahashi, Alessandro Mannucci, Kunitoshi Shigeyasu, et al.
Cancers|February 13, 2025
Metabolic Singularities in Microsatellite-Stable Colorectal Cancer: Identifying Key Players in Immunosuppression to Improve the Immunotherapy ResponseTeresa Gorría, Marina Sierra-Boada, Mariam Rojas, et al.
Journal of Neurology|March 8, 2022
Prognostic value of cutaneous reinnervation with GAP-43 in oxaliplatin-induced neuropathyMerve Albayrak, Carolina Figueras, Elia Seguí, et al.
Revista Espanola De Enfermedades Digestivas|July 4, 2015
Endoluminal brachytherapy in the treatment of oesophageal cancer. Technique description, case report and review of the literatureLuisa Castilla, Ángeles Rovirosa, Àngels Ginés, et al.
Plos One|March 7, 2009
The role of MMP7 and its cross-talk with the FAS/FASL system during the acquisition of chemoresistance to oxaliplatinVanessa Almendro, Elisabet Ametller, Susana García-Recio, et al.
Exploration of Targeted Anti-Tumor Therapy|September 29, 2025
Metabolic plasticity drives specific mechanisms of chemotherapy and targeted therapy resistance in metastatic colorectal cancerMariam Rojas, Malena Manzi, Sergio Madurga, et al.
Pageof 12

Showing results (11-20 of 116) with videos related to

Sort By:
Pageof 12
International Journal of Cancer|October 22, 2014
Why post-progression survival and post-relapse survival are not appropriate measures of efficacy in cancer randomized clinical trialsXabier García-Albéniz, Joan Maurel, Miguel A Hernán
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 9, 2011
SEOM clinical guidelines for the treatment of anal cancerJoan Maurel, Carlos Fernández-Martos, Jaime Feliu, et al.
Cancers|August 17, 2019
The Tumor Microenvironment in Colorectal Cancer TherapyLeire Pedrosa, Francis Esposito, Timothy M Thomson, et al.
Journal of Clinical Medicine|March 6, 2021
Are Quality of Randomized Clinical Trials and ESMO-Magnitude of Clinical Benefit Scale Two Sides of the Same Coin, to Grade Recommendations for Drug Approval?Adela Rodriguez, Francis Esposito, Helena Oliveres, et al.
JCO Precision Oncology|May 18, 2026
EXONERATE-TRaCE: A Liquid Biopsy for Tracking Response to Anti-Epidermal Growth Factor Receptor-Based Therapy in Metastatic Colorectal CancerToshiaki Takahashi, Alessandro Mannucci, Kunitoshi Shigeyasu, et al.
Cancers|February 13, 2025
Metabolic Singularities in Microsatellite-Stable Colorectal Cancer: Identifying Key Players in Immunosuppression to Improve the Immunotherapy ResponseTeresa Gorría, Marina Sierra-Boada, Mariam Rojas, et al.
Journal of Neurology|March 8, 2022
Prognostic value of cutaneous reinnervation with GAP-43 in oxaliplatin-induced neuropathyMerve Albayrak, Carolina Figueras, Elia Seguí, et al.
Revista Espanola De Enfermedades Digestivas|July 4, 2015
Endoluminal brachytherapy in the treatment of oesophageal cancer. Technique description, case report and review of the literatureLuisa Castilla, Ángeles Rovirosa, Àngels Ginés, et al.
Plos One|March 7, 2009
The role of MMP7 and its cross-talk with the FAS/FASL system during the acquisition of chemoresistance to oxaliplatinVanessa Almendro, Elisabet Ametller, Susana García-Recio, et al.
Exploration of Targeted Anti-Tumor Therapy|September 29, 2025
Metabolic plasticity drives specific mechanisms of chemotherapy and targeted therapy resistance in metastatic colorectal cancerMariam Rojas, Malena Manzi, Sergio Madurga, et al.
Pageof 12